These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 17703896

  • 1. 10-year survival and quality of life in patients with high-risk pN0 prostate cancer following definitive radiotherapy.
    Berg A, Lilleby W, Bruland OS, Fosså SD.
    Int J Radiat Oncol Biol Phys; 2007 Nov 15; 69(4):1074-83. PubMed ID: 17703896
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for localized prostate cancer.
    Frank SJ, Pisters LL, Davis J, Lee AK, Bassett R, Kuban DA.
    J Urol; 2007 Jun 15; 177(6):2151-6; discussion 2156. PubMed ID: 17509305
    [Abstract] [Full Text] [Related]

  • 4. Postradiotherapy 2-year prostate-specific antigen nadir as a predictor of long-term prostate cancer mortality.
    Zelefsky MJ, Shi W, Yamada Y, Kollmeier MA, Cox B, Park J, Seshan VE.
    Int J Radiat Oncol Biol Phys; 2009 Dec 01; 75(5):1350-6. PubMed ID: 19515504
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Disease-specific symptoms and general quality of life of patients with prostate carcinoma before and after primary three-dimensional conformal radiotherapy.
    Staff I, Salner A, Bohannon R, Panatieri P, Maljanian R.
    Cancer; 2003 Dec 01; 98(11):2335-43. PubMed ID: 14635067
    [Abstract] [Full Text] [Related]

  • 8. Health-related quality of life measurement in long-term survivors and outcome following radical radiotherapy for localized prostate cancer.
    Galalae RM, Loch T, Riemer B, Rzehak P, Küchler T, Kimmig B, Kovács G.
    Strahlenther Onkol; 2004 Sep 01; 180(9):582-9. PubMed ID: 15378189
    [Abstract] [Full Text] [Related]

  • 9. Health-related quality of life after intensity modulated radiation therapy for localized prostate cancer: comparison with conventional and conformal radiotherapy.
    Namiki S, Ishidoya S, Tochigi T, Kawamura S, Kuwahara M, Terai A, Yoshimura K, Numata I, Satoh M, Saito S, Takai Y, Yamada S, Arai Y.
    Jpn J Clin Oncol; 2006 Apr 01; 36(4):224-30. PubMed ID: 16537689
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Late side effects unchanged 4-8 years after radiotherapy for prostate carcinoma: a comparison with age-matched controls.
    Fransson P, Widmark A.
    Cancer; 1999 Feb 01; 85(3):678-88. PubMed ID: 10091741
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Definitive conformal radiotherapy for localized prostate cancer: a long-term follow-up study.
    Deichmueller CM, Wegener G, Karstens JH, Bruns F.
    Anticancer Res; 2009 Jul 01; 29(7):2627-34. PubMed ID: 19596938
    [Abstract] [Full Text] [Related]

  • 14. Long-term outcome following three-dimensional conformal/intensity-modulated external-beam radiotherapy for clinical stage T3 prostate cancer.
    Zelefsky MJ, Yamada Y, Kollmeier MA, Shippy AM, Nedelka MA.
    Eur Urol; 2008 Jun 01; 53(6):1172-9. PubMed ID: 18222596
    [Abstract] [Full Text] [Related]

  • 15. Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes.
    Zelefsky MJ, Yamada Y, Fuks Z, Zhang Z, Hunt M, Cahlon O, Park J, Shippy A.
    Int J Radiat Oncol Biol Phys; 2008 Jul 15; 71(4):1028-33. PubMed ID: 18280056
    [Abstract] [Full Text] [Related]

  • 16. Neoadjuvant hormonal therapy impairs sexual outcome among younger men who undergo external beam radiotherapy for localized prostate cancer.
    Hollenbeck BK, Wei JT, Sanda MG, Dunn RL, Sandler HM.
    Urology; 2004 May 15; 63(5):946-50. PubMed ID: 15134986
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Hypofractionated boost with high-dose-rate brachytherapy and open magnetic resonance imaging-guided implants for locally aggressive prostate cancer: a sequential dose-escalation pilot study.
    Ares C, Popowski Y, Pampallona S, Nouet P, Dipasquale G, Bieri S, Ozsoy O, Rouzaud M, Khan H, Miralbell R.
    Int J Radiat Oncol Biol Phys; 2009 Nov 01; 75(3):656-63. PubMed ID: 19250768
    [Abstract] [Full Text] [Related]

  • 20. Prostate brachytherapy in men > or =75 years of age.
    Merrick GS, Wallner KE, Galbreath RW, Butler WM, Brammer SG, Allen ZA, Adamovich E.
    Int J Radiat Oncol Biol Phys; 2008 Oct 01; 72(2):415-20. PubMed ID: 18374514
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.